116 related articles for article (PubMed ID: 19591405)
21. 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
Fink-Bennett DM; Thomas K
J Nucl Med Technol; 2003 Jun; 31(2):61-8; quiz 69-70. PubMed ID: 12777454
[TBL] [Abstract][Full Text] [Related]
22. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.
Esmaeli B; McLaughlin P; Pro B; Samaniego F; Gayed I; Hagemeister F; Romaguera J; Cabanillas F; Neelapu SS; Banay R; Fayad L; Wayne Saville M; Kwak LW
Ann Oncol; 2009 Apr; 20(4):709-14. PubMed ID: 19150940
[TBL] [Abstract][Full Text] [Related]
23. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
Ulaner GA; Colletti PM; Conti PS
Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
[TBL] [Abstract][Full Text] [Related]
24. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
[TBL] [Abstract][Full Text] [Related]
25. Unsuspected pneumonia detected by increased lung uptake on 111In-ibritumomab tiuxetan scan.
Hwang M; Joyce JM; Klein H; Hou JZ
Clin Nucl Med; 2012 Oct; 37(10):1003-5. PubMed ID: 22955077
[TBL] [Abstract][Full Text] [Related]
26. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Zimmer AM
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
[TBL] [Abstract][Full Text] [Related]
27. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
[TBL] [Abstract][Full Text] [Related]
28. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.
Tsimberidou AM; Murray JL; O'Brien S; Wierda WG; Keating MJ
Cancer; 2004 May; 100(10):2195-200. PubMed ID: 15139064
[TBL] [Abstract][Full Text] [Related]
29. 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution.
Matesan M; Rajendran J; Press OW; Maloney DG; Storb RF; Cassaday RD; Pagel JM; Oliveira G; Gopal AK
Nucl Med Commun; 2014 Nov; 35(11):1132-42. PubMed ID: 25076159
[TBL] [Abstract][Full Text] [Related]
30. The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: two cases of abnormal biodistribution.
Aricò D; Grana CM; Vanazzi A; Ferrari M; Mallia A; Sansovini M; Martinelli G; Paganelli G; Cremonesi M
Cancer Biother Radiopharm; 2009 Apr; 24(2):271-5. PubMed ID: 19409050
[TBL] [Abstract][Full Text] [Related]
31. Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Storto G; De Renzo A; Pellegrino T; Perna F; De Falco T; Erra P; Nardelli A; Speranza A; Klain M; Rotoli B; Pace L
Radiology; 2010 Jan; 254(1):245-52. PubMed ID: 20032155
[TBL] [Abstract][Full Text] [Related]
32. Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Schilder R; Molina A; Bartlett N; Witzig T; Gordon L; Murray J; Spies S; Wang H; Wiseman G; White C
Cancer Biother Radiopharm; 2004 Aug; 19(4):478-81. PubMed ID: 15453962
[TBL] [Abstract][Full Text] [Related]
33. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma.
Krasner C; Joyce RM
Curr Pharm Biotechnol; 2001 Dec; 2(4):341-9. PubMed ID: 11762415
[TBL] [Abstract][Full Text] [Related]
34. First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma.
Maza S; Kiewe P; Munz DL; Korfel A; Hamm B; Jahnke K; Thiel E
Neuro Oncol; 2009 Aug; 11(4):423-9. PubMed ID: 19060176
[TBL] [Abstract][Full Text] [Related]
35. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
Weigert O; Illidge T; Hiddemann W; Dreyling M
Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
[TBL] [Abstract][Full Text] [Related]
36. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin).
Tennvall J; Fischer M; Bischof Delaloye A; Bombardieri E; Bodei L; Giammarile F; Lassmann M; Oyen W; Brans B; ; ;
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):616-22. PubMed ID: 17323056
[TBL] [Abstract][Full Text] [Related]
37. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
Witzig TE; White CA; Gordon LI; Wiseman GA; Emmanouilides C; Murray JL; Lister J; Multani PS
J Clin Oncol; 2003 Apr; 21(7):1263-70. PubMed ID: 12663713
[TBL] [Abstract][Full Text] [Related]
38. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma.
Doolittle ND; Jahnke K; Belanger R; Ryan DA; Nance RW; Lacy CA; Tyson RM; Haluska M; Hedrick NA; Varallyay C; Neuwelt EA
Leuk Lymphoma; 2007 Sep; 48(9):1712-20. PubMed ID: 17786706
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of ⁹⁰Yttrium-ibritumomab tiuxetan in relapsed/refractory extranodal marginal-zone lymphoma.
Vanazzi A; Grana C; Crosta C; Pruneri G; Rizzo S; Radice D; Pinto A; Calabrese L; Paganelli G; Martinelli G
Hematol Oncol; 2014 Mar; 32(1):10-5. PubMed ID: 23696416
[TBL] [Abstract][Full Text] [Related]
40. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
